trending Market Intelligence /marketintelligence/en/news-insights/trending/Sb9n1MCQDo6u26yeK-6ukQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Swiss billionaire Bertarelli's Waypoint Capital to buy out Stallergenes Greer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Swiss billionaire Bertarelli's Waypoint Capital to buy out Stallergenes Greer

Ares Life Sciences I Sarl — also known as Waypoint Capital, the investment vehicle backed by Swiss billionaire Ernesto Bertarelli — is buying out Stallergenes Greer PLC and taking it private.

Under the agreement, Waypoint will acquire the entire issued and to be issued ordinary shares of Stallergenes Greer not already held by Waypoint for €37 per share in cash, representing a 42.9% premium to Stallergenes' closing share price of €25.90 on March 20. The buyout is expected to take effect in May.

Waypoint held an 83.86% stake in Stallergenes as of April 13, 2018, according to S&P Global Market Intelligence data.

Following the deal, Stallergenes, a London-based biopharmaceutical company focused on allergy therapies, will be delisted from the regulated market of Euronext Paris. "[I]n light of Stallergenes Greer's limited public float, Waypoint has concluded that the benefits of having shares publicly listed are limited, and the costs of maintaining such listing are not justified for shareholders," Waypoint said.

Waypoint intends to finance the transaction through a new debt facility.

The transaction is subject to certain conditions, including approvals from Stallergenes shareholders and the High Court of Justice of England and Wales.

Evercore Partners International LLP serves as financial adviser to Stallergenes. UBS AG London Branch acts as financial adviser to Waypoint.